ProCE Banner Series

Experts Highlight the Most Important Advances in HR+/HER2- Breast Cancer

Join us online for this interactive webinar with experts highlighting their choices of the most impactful trials from the past year and how they have adapted their clinical practice for the management of patients with HR+/HER2- breast cancer along with a preview of soon to be reported trials that may change practice in 2025.

  ACPE
  | AMA
Who Should Attend

This program is intended for physicians, pharmacists, and other healthcare professionals caring for patients with breast cancer.

All Events

Experts Highlight the Most Important Advances in HR+/HER2- Breast Cancer

Upcoming Events

April

29

2025

1:00 PM - 2:00 PM Eastern Time (ET)

Virtual

Topics

Breast Cancer

Additional Info

There are no fees required to participate in this activity.

Americans With Disabilities Act 
Event staff will be glad to assist you with any special needs (eg, physical, dietary). Please contact customer support prior to the live event.

CME/CE Info

Goal Statement
The goal of this program is to improve the knowledge and competence of learners in effort to optimize treatment for patients with Breast Cancer.

Target Audience
This program is intended for physicians, pharmacists, and other healthcare professionals caring for patients with breast cancer.

Learning Objectives
Upon completion of this event, participants should be able to:

  • Integrate biomarker testing into identification of patients with HR+/HER2- metastatic breast cancer likely to benefit from investigational or approved therapies
  • Plan optimal neoadjuvant/adjuvant treatment strategies incorporating novel targeted therapies to reduce the risk of recurrence in patients with HR+/HER2- early breast cancer
  • Synthesize recently presented data, guidelines, and expert recommendations to develop individualized treatment plans leveraging investigational or approved therapies for patients with HR+/HER2- metastatic breast cancer
  • Educate patients and colleagues on clinically important differences in safety profiles for novel vs established therapies for patients with HR+/HER2- breast cancer

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

Physician Continuing Medical Education

CCO designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Pharmacy Education

CCO designates this continuing education activity for 1.0 contact hour (0.1 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number: JA4008176-0000-25-145-L01-P 

Type of Activity: Application

Upon successfully completing the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 60 days.

CME Passport

A logo for a companyDescription automatically generated

The CME credits that physicians earn from this activity will be submitted to ACCME's CME Passport, a free, centralized web application where you can create a personalized account to view, track, and generate transcripts of your reported CME credit. Visit www.cmepassport.org to create your account.

Disclosure of Conflicts of Interest
Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

Acknowledgement

Provided by Clinical Care Options, LLC.

Supported by educational grants from Lilly and Stemline Therapeutics, Inc.

For customer support please click here.

Mailing Address:

 

Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191